Headquartered in Durban, South Africa, we are a global specialty and branded pharmaceutical company, improving the health of patients across the world through our high quality and affordable medicines. Active at every stage of the value chain, we are uniquely diversiﬁed by geography, product and manufacturing capability.
With an acknowledged presence of more than two decades in the pharmaceutical sector, we improve the health of patients in more than 115 countries. The Group’s key business segments are Manufacturing and Commercial Pharmaceuticals comprising Regional Brands and Sterile Focus Brands.
December 2022 Annual General Meeting
Africa Middle East
This region consists of 45 countries and is the number one region in the Commercial Pharmaceuticals segment by revenue, mainly driven by South Africa. Across the multiple countries in the region, commercial and sales employees not only support well-established local brands, but also internationally recognised medicines, with both having strong brand equity attributes. The primary manufacturing site in the region is in Gqeberha, South Africa, which has manufacturing capabilities extending to steriles and biologicals that are extensive, niche and differentiated including high potency and hormonal solids, as well as vaccines and other state-of-the-art sterile
capabilities. There are two further regional manufacturing sites in South Africa which are located in Cape Town and East London. Additional regional sites in Africa are in Ghana, Kenya and Tanzania.
Kingdom of Saudi Arabia
United Arab Emirates
The South African private pharmaceutical sector was valued at R52,04 billion MAT** for the period ended June 2022.
Aspen is ranked as the number one pharmaceutical company in the South African private sector with a 9,40% share by value.
By 2025, Middle East & Africa (“MEA”) pharma market is collectively estimated to be USD56 billion, with UAE and Egypt contributing 24,0% and 17,4% respectively.
Middle East, North Africa & Turkey (“MENAT”) pharmaceutical market is expected to grow by 4,63% CAGR from 2021 – 2024, driven mainly by Turkey and Egypt.
Sources: IQVIA TPM MAT** June 2022, IQVIA Middle East & Africa Pharmaceutical Market Insights – Released June 2022; Source: IQVIA May 2022 MAT.
** Moving annual total.
Latin America continues to dominate this region, with Mexico and Brazil being the most significant contributors to the region’s performance. There is one manufacturing site in this region which is situated in Brazil and which focuses on finished dose form (“FDF”). The region commercialises internationally recognised medicines across the prescription, hospital and over-the-counter (“OTC”) channels.
The Mexican pharmaceutical market grew
8% to EUR9,01 billion MAT June 2022,
positively impacted by growth across the
generic, ethical and OTC markets.
Pharmaceutical sales across the total
Spanish Latin America market grew 13,6%
to EUR22,5 billion MAT June 2022.
Source: IQVIA – June 2022
MAT= Moving annual total
The region is the largest contributor to the Group’s Sterile Focus Brands revenue and comprises all Asian territories including China. Active trading subsidiaries include those in China, the Philippines, Taiwan, and Malaysia with other countries and territories in the region such as Hong Kong reached via distributors. The region has one manufacturing site in Hyderabad, India, which is focused on new product development.
China’s pharmaceutical market including
hospital and retail channels is expected
to grow at 2,4% CAGR (2021 to 2026).
The market is expected to be valued at
RMB1,234 billion by 2026.
The Korea total pharmaceutical market grew
8,2% MAT Q1 2022 versus Q1 MAT 2021.
Source: IQVIA Market Prognosis 2022M03 & IQVIA MAT 2022
Q1 Vs MAT 2021 Q1
MAT = Moving annual total.
After Africa, Aspen Australasia is the second largest revenue contributor to Regional Brands, with a comprehensive portfolio of medicines comprising Regional and Global Brands, including prescription and OTC products, as well as Sterile Focus Brands. There is also a manufacturing site in Australia, which produces FDF and undertakes third-party manufacturing.
The Australia and New Zealand OTC market
was valued at AUD4,5 billion in June 2022
and grew 12,9% driven by recovery of
various therapeutic segments specifically the
Cough/Cold/Flu and related segments as a
result of stay-at-home COVID-19 treatments
and severe cold and flu season.
The total pharmaceutical segment excluding
the grocery channel grew 9,2% June 2022.
Source: IQVIA June 2022
Europe CIS provides a broad range of Sterile Focus and Regional Brands and undertakes third-party manufacturing. The revenue contribution from the Sterile Focus Brands portfolio is the second highest after Asia, and consists of Anaesthetics and to a lesser extent Thrombosis products in Russia and the Europe CIS region. The manufacturing operations, which span across both active pharmaceutical ingredients (“APIs”) and FDF production, are widely accredited and provide a variety of technologies for Aspen’s own commercialisation strategy and for third-party use.